Will AI Innovation at the 2025 Veeva Summit Shift Veeva Systems' (VEEV) Long-Term Growth Narrative?

• Earlier this month, Veeva Systems hosted its 2025 Veeva Commercial Summit in Spain, featuring presentations from senior leaders across product, consulting, and AI teams on the company's latest innovations and solutions for life sciences clients.
• The conference highlighted Veeva's ongoing investment in AI-driven cloud products and deepened engagement with European and global pharmaceutical customers, underscoring its role as a technology partner in the digitization of the healthcare sector.
• In light of the summit’s focus on AI integration and commercial product updates, we'll explore how these developments may influence Veeva's long-term growth narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Veeva Systems Investment Narrative Recap

For someone to be a shareholder in Veeva Systems, you have to believe in the company’s ability to stay at the forefront of the digital transformation in life sciences, particularly through AI-powered cloud solutions and growing international customer adoption. The Commercial Summit in Spain spotlighted further AI integration but didn’t materially shift the near-term earnings catalyst, the pending Q3 results, nor did it ease concerns about intensifying competition from tech giants, which remains the biggest short-term risk to watch.

Among the latest updates, Veeva’s announcement that Gilead Sciences has committed to adopting Vault CRM, leveraging AI agents for commercial execution, stands out in light of recent conference themes around automation and advanced analytics. Progress with such major clients tie directly into the thesis that expanding enterprise relationships and market share in pharma can help drive recurring revenue and improve earnings visibility.

On the other hand, investors should also be aware of the increasing threat posed by heavyweight competitors expanding their offerings into healthcare verticals, since...

Read the full narrative on Veeva Systems (it's free!)

Veeva Systems' narrative projects $4.3 billion revenue and $1.3 billion earnings by 2028. This requires 12.8% yearly revenue growth and a $490 million earnings increase from $809.9 million.

Uncover how Veeva Systems' forecasts yield a $320.62 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Seven members of the Simply Wall St Community estimate Veeva’s fair value between US$230 and US$320.62. While views differ, many see the risk from rising competition as having broad implications for future margins and growth, explore alternative viewpoints and see where your own analysis fits in.

Explore 7 other fair value estimates on Veeva Systems - why the stock might be worth 22% less than the current price!

Build Your Own Veeva Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Veeva Systems research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com